A qui tam action is a lawsuit filed by a private person (often a whistleblower) on behalf of the government to recover money lost to fraud, with the filer eligible to receive a share of any recovery. Think of it as a neighbor reporting and suing on behalf of the city, then getting a reward if the city wins. Investors should care because qui tam cases can trigger large fines, settlements, legal costs, accounting changes and damage to reputation that materially affect a company’s value.
department of justiceregulatory
A Department of Justice is a government agency that enforces laws, prosecutes criminal cases, and oversees legal actions against individuals and organizations. It matters to investors because its investigations, lawsuits, or fines can change a company’s costs, leadership, or ability to operate—similar to a referee calling penalties in a game, its decisions can shift a company’s value and market confidence.
united states district courtregulatory
A United States District Court is a federal trial-level court that hears cases involving federal law, disputes between parties from different states, and some matters like enforcement actions and injunctions. Think of it as a courtroom where a judge (and sometimes a jury) resolves legal fights that can decide whether a company faces fines, must change its practices, or is liable for damages—outcomes that can directly affect a company’s finances and stock value.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
BRISBANE, Calif.--(BUSINESS WIRE)--
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the dismissal of a qui tam action filed against the Company.
On April 23, 2026, the United States District Court for the Eastern District of New York issued an order dismissing the matter.
There is no monetary payment associated with the dismissal.
The dismissal order follows the request, by the qui tam plaintiff, for dismissal of the case and the Department of Justice's (DOJ) concurrence in that request.
The matter was initially filed on February 12, 2021 and led to a DOJ investigation. On October 8, 2024, CareDx announced that the DOJ had concluded its investigation into CareDx without any finding of wrongdoing and declined to take further action. CareDx has denied allegations of wrongdoing throughout.
About CareDx
CareDx is a precision medicine company dedicated to improving outcomes for transplant patients and advancing organ health. The Company’s integrated solutions include non‑invasive molecular testing for heart, kidney, and lung transplants; laboratory products; digital health technologies; and patient solutions that support care before and after transplant. CareDx is the leading provider of genomics‑based information for transplant patients. For more information, please visit www.caredx.com.
